SCHEMBL29384605

SCHEMBL29384605

Cc1ccc(S(=O)(=O)OCC2CO[C@H](COCc3ccccc3)[C@H](OCc3ccccc3)[C@@H]2OCc2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ TACR2 P21452 3/20 0.38
▸ NT5E P21589 1/20 0.38
▸ BCHE P06276 2/20 0.36
▸ ACHE P22303 2/20 0.36
▸ FGF1 P05230 2/20 0.36
▸ FGF2 P09038 2/20 0.36
▸ VEGFA P15692 2/20 0.36
▸ HPSE Q9Y251 2/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ PTPN1 P18031 2/20 0.35
▸ PTPN2 P17706 1/20 0.35
▸ PTPN11 Q06124 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23705219 1.00 CA1 (0.42) CA1CA2CA9TACR2NT5E
SCHEMBL26879181 0.92 CA1 (0.39) CA1CA2CA9TACR2NT5E
SCHEMBL8720284 0.88 CA1 (0.49) CA1CA2CA9TACR2NT5E
SCHEMBL20147260 0.85 FGF1 (0.40) CA1CA2CA9BCHEACHE
SCHEMBL16224526 0.84 TUBB4A (0.38) CA1CA2CA9BCHEACHE
SCHEMBL29381346 0.81 KCNA5 (0.47) CA1CA2CA9TACR2NT5E
SCHEMBL14410760 0.80 FGF1 (0.45) CA1CA2CA9TACR2NT5E
SCHEMBL14410762 0.80 FGF1 (0.45) CA1CA2CA9TACR2NT5E
SCHEMBL26879797 0.79 — —
SCHEMBL28316892 0.79 FGF1 (0.52) CA1CA2CA9NT5EBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
WO-2022035997-A1 IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS AVILAR THERAPEUTICS, INC. (US) 2022-02-17 — — WO disclosed
Send feedback